

## FAST FACTS >

1

In the past 5 years, new therapeutic agents with molecular targets have emerged as options for radioactive iodine-refractory thyroid cancer.

---

2

Because thyroid cancer can be slow progress, whether to treat patients and expose them to side effects of therapy is an important clinical decision.

---

3

Incorporating these new treatments will require oncologists and endocrinologists to become adept at managing their effects.

**HemOnc**today